Merus N.V. (MRUS) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Sven Ante Lundberg	Chief Executive Officer, President & Executive Director	1.24M	1963
Jan van de Winkel	CEO & Executive Director	0	N/A
Cornelis Adriaan de Kruif	Chief Technology Officer & Executive Vice President	380,471	1964
Fabian Zohren	Chief Medical Officer	637,930	1976
Gregory D. Perry	Chief Financial Officer	757,509	1960
Peter Silverman	EVice President, Company Secretary, Chief Operating Officer, General Counsel, Chief Intellectual Property Officer & Head of US Legal	895,170	1978
Cecilia Anna Wilhelmina Geuijen	Chief Scientific Officer & Senior Vice President	0	N/A
Kathleen Farren	Director of IR & Corporate Communications Officer	0	N/A
Sherri Spear	Senior Vice President of Investor Relations & Strategic Communications	0	N/A
Harry Shuman	Chief Accounting Officer	0	N/A
Hennie Hoogenboom	Co-Founder and Scientific Advisor	0	N/A

Name

Title

Pay

Year Born

Sven Ante Lundberg

Chief Executive Officer, President & Executive Director

1.24M

1963

Jan van de Winkel

CEO & Executive Director

N/A

Cornelis Adriaan de Kruif

Chief Technology Officer & Executive Vice President

380,471

1964

Fabian Zohren

Chief Medical Officer

637,930

1976

Gregory D. Perry

Chief Financial Officer

757,509

1960

Peter Silverman

EVice President, Company Secretary, Chief Operating Officer, General Counsel, Chief Intellectual Property Officer & Head of US Legal

895,170

1978

Cecilia Anna Wilhelmina Geuijen

Chief Scientific Officer & Senior Vice President

N/A

Kathleen Farren

Director of IR & Corporate Communications Officer

N/A

Sherri Spear

Senior Vice President of Investor Relations & Strategic Communications

N/A

Harry Shuman

Chief Accounting Officer

N/A

Hennie Hoogenboom

Co-Founder and Scientific Advisor

N/A

Description

Merus N.V. is a clinical-stage immuno-oncology firm based in the Netherlands, specializing in the discovery and advancement of bispecific antibody therapies. Established in 2003, the company maintains its headquarters in Utrecht. Its robust pipeline of bispecific antibody candidates includes Zenocutuzumab (MCLA-128), which is currently undergoing Phase 2 clinical trials for the treatment of patients with metastatic breast cancer, and is also in Phase 1/2 clinical trials for solid tumors that exhibit Neuregulin 1 expression. Merus is also actively developing several other compounds: MCLA-158: In Phase 1 clinical trials for solid tumors. MCLA-145: Also in Phase 1 clinical trials for various solid tumors. MCLA-129: Progressing through Phase 1/2 clinical trials for advanced non-small cell lung cancer (NSCLC) and other solid tumors. ONO-4685: Currently in Phase 1 clinical trials to address relapsed/refractory T-cell lymphoma. Furthermore, Merus engages in strategic partnerships. It collaborates with Betta Pharmaceuticals Co. Ltd on the research and development of specific bispecific antibody candidates, including MCLA-129. Additionally, Incyte Corporation is partnering with Merus for the development of MCLA-145.